New Pancreatic Cancer Pill Doubles Survival, Blood Test for Colon Cancer Sparks Debate, FDA Fast‑Track Granted to Lung‑c

Revolution Medicines announced that its experimental oral drug Daraxonrasib more than doubled median overall survival for patients with advanced pancreatic cancer, extending life to 13 months compared with standard chemotherapy. The result will be presented at the upcoming American Society of Clinical Oncology meeting, and U.S. regulators have already begun expanding access while the therapy undergoes further review.

The American Cancer Society updated its screening guidelines to include a simple blood test (Shield) that detects tumor‑derived DNA fragments for colorectal cancer. While the test could increase screening uptake, experts caution that it misses many early‑stage lesions and should be used only when colonoscopy or stool‑based tests are not feasible.

Separately, the U.S. Food and Drug Administration granted fast‑track status to Verastem’s lung‑cancer program, a regulatory designation that allows more frequent interaction with the agency and may accelerate development and review.

Additional oncology news notes recent approvals of several targeted therapies for breast, bladder, lung, colorectal and other cancers, expanding treatment options across multiple tumour types.